BD has secured authorisations in the EU and US for its new molecular laboratory COVID-19 test. The test screens for the virus, emerging variants from the UK and South Africa and influenza A and B.
The test is designed to deliver results within 2-3 hours and can process hundreds of samples daily on the BD MAX platform.
BD utilised computer analyses to assess the test’s accuracy against variants such as the emerging B.1.1.7 and B.1.351 strains which were first identified in the UK and South Africa.
Analyses showed that 99.9 per cent of the genetic sequences found in these variants would match the molecular targets in BD’s tests, its combined diagnostic and its standalone COVID-19 screeners.
BD’s diagnostics Vice-President for medical and scientific affairs Charles Cooper said: "The guidelines from the U.S. Centers for Disease Control and Prevention recommend testing for both Flu and SARS-CoV-2 for all patients who are hospitalized and for patients who will not be hospitalized but for whom a positive result will change clinical management.”
"Since COVID-19 and Flu often present with similar symptoms, such as fever and dry cough, having a single specimen for accurate diagnosis speeds time to results and helps clinicians determine the right care more quickly to help prevent community transmission.”